CancerDetect™ minimal residual disease test
An innovative, personalised liquid biopsy test designed to assess relapse risk in patients with stage I–III solid tumours. The test is based on tumour genetic analysis and enables ultra-early detection of minimal residual disease signals.
Invisible risk after treatment: what can residual disease hide?
Even after successful treatment, patients with stage I–III solid tumours remain at risk of recurrence. Traditional imaging methods do not always detect minimal residual disease early enough.
By combining tumour analysis with personalised sequencing, CancerDetect™ can identify relapse signals significantly earlier – when action can still be taken.
How does CancerDetect™ work?
CancerDetect™ is a personalised liquid biopsy test based on tumour genetic analysis. It creates an individualised genetic marker panel to precisely monitor disease course and detect relapse signals before clinical or radiological signs appear.
Tumour analysis using whole-exome sequencing (WES)
Personalised target panel with up to 500 markers (individual + therapeutic)
Liquid biopsy analysis of circulating tumour DNA (ctDNA) in blood
Detection sensitivity: down to 0.001%
Early recurrence detection and support for adjuvant treatment planning
Benefits for post-treatment patient monitoring
CancerDetect™ enables early detection of tumour recurrence signals and supports clinicians in making evidence-based decisions regarding further treatment or follow-up. Because the test is grounded in the tumour’s individual genetic information and has extremely high sensitivity, relapse risk can be assessed more accurately before clinical symptoms develop.
Personalised disease monitoring
A patient-specific marker panel is created, enabling precise tracking of an individual’s disease course.
Early detection of relapse signals
CancerDetect™ detects minimal residual disease with sensitivity down to 0.001% – well before imaging studies.
Support for adjuvant treatment decisions
Results help clinicians assess whether additional treatment is needed to reduce the risk of disease returning.
Non-invasive and suitable for repeat testing
As a blood-based liquid biopsy, the test can be repeated safely and regularly.
When and for whom is the test recommended?
For patients after surgical treatment for stage I–III solid tumours
CancerDetect™ helps assess whether minimal residual disease remains – changes that may not be visible on standard imaging.
For clinicians planning adjuvant therapy
Provides a clearer basis for decisions on chemotherapy or immunotherapy after surgery.
When recurrence risk is elevated
Personalised genetic monitoring enables much earlier detection of relapse signals and timely intervention.
For patients who need long-term, non-invasive follow-up
Liquid biopsy is a painless, repeatable approach suitable for routine disease monitoring.
CancerDetect™ reliability: accuracy and quality metrics
CancerDetect™ uses hybrid-capture next-generation sequencing (NGS) with ultra-deep coverage of >100,000×. The test is based on each patient’s tumour genetic information, enabling highly accurate identification of minimal residual disease (MRD) markers.
0.001% detection sensitivity
Up to 500 individualised targets (including therapeutic targets)
100,000× sequencing depth using HQS™ technology
Personalised cancer recurrence monitoring
Take the CancerDetect™ test to find out whether minimal residual disease remains in your body.
For Specialists
All key information in one place – from panel content to accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
CancerDetect™ combines whole-exome sequencing (WES) of tumour tissue with targeted liquid biopsy analysis using patented HQS™ technology. Tumour DNA analysis is used to create an individualised marker panel, and ultra-deep ctDNA sequencing from blood (≥100,000×) enables highly sensitive MRD detection.
The test detects minimal residual disease down to 0.001%. A panel of up to 500 targets is used, including approximately ~100 personalised targets derived from tumour WES results and ~50 known therapeutic targets. This broad, individualised target spectrum supports high sensitivity and clinical value for early relapse detection.
Intended for patients after surgical treatment for stage I–III solid tumours to:
- assess MRD presence,
- support decisions on adjuvant therapy,
- monitor for relapse earlier than radiological detection.
Two samples are required:
- FFPE tissue (10 sections of 10 µm; tumour content ≥30%) to determine tumour genotype,
- ≥20 ml venous blood for ctDNA analysis.
Genetic sequences are compared against the tumour profile and specific mutations are monitored over time.
CancerDetect™ has been validated in large, multicentre studies, particularly in colorectal cancer cohorts. Results showed that a positive MRD signal strongly correlates with poorer survival prognosis – even in the absence of radiological evidence of relapse.
